
Harry J De Koning

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9422880/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Screening and Prostate-Cancer Mortality in a Randomized European Study. New England Journal of Medicine, 2009, 360, 1320-1328.	13.9	3,540
2	Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. New England Journal of Medicine, 2020, 382, 503-513.	13.9	1,836
3	Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition. New England Journal of Medicine, 2004, 351, 427-437.	13.9	1,563
4	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, The, 2014, 384, 2027-2035.	6.3	1,261
5	Prostate-Cancer Mortality at 11 Years of Follow-up. New England Journal of Medicine, 2012, 366, 981-990.	13.9	1,105
6	Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer. Journal of the National Cancer Institute, 2003, 95, 868-878.	3.0	951
7	Management of Lung Nodules Detected by Volume CT Scanning. New England Journal of Medicine, 2009, 361, 2221-2229.	13.9	758
8	Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context. Journal of the National Cancer Institute, 2009, 101, 374-383.	3.0	668
9	Effects of Mammography Screening Under Different Screening Schedules: Model Estimates of Potential Benefits and Harms. Annals of Internal Medicine, 2009, 151, 738.	2.0	509
10	Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). International Journal of Cancer, 2007, 120, 868-874.	2.3	437
11	European position statement on lung cancer screening. Lancet Oncology, The, 2017, 18, e754-e766.	5.1	428
12	Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncology, The, 2014, 15, 1332-1341.	5.1	424
13	Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. New England Journal of Medicine, 2019, 381, 2091-2102.	13.9	388
14	Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2014, 160, 311.	2.0	377
15	Quality-of-Life Effects of Prostate-Specific Antigen Screening. New England Journal of Medicine, 2012, 367, 595-605.	13.9	364
16	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 2019, 76, 43-51.	0.9	359
17	Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review. Journal of Medical Screening, 2012, 19, 42-56.	1.1	338
18	Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer, 2006, 54, 177-184.	0.9	313

#	Article	IF	CITATIONS
19	Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet, The, 2003, 361, 1411-1417.	6.3	310
20	Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nature Genetics, 2017, 49, 426-432.	9.4	306
21	Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers. Lancet Oncology, The, 2014, 15, 1342-1350.	5.1	294
22	PROSTATE CANCER DETECTION AT LOW PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2000, 163, 806-812.	0.2	277
23	Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram. Journal of Urology, 2007, 177, 107-112.	0.2	271
24	Large-scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. International Journal of Cancer, 2002, 97, 237-244.	2.3	247
25	Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology, 2016, 11, 613-638.	0.5	231
26	First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Research and Treatment, 2000, 63, 53-60.	1.1	216
27	Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study. PLoS Medicine, 2017, 14, e1002277.	3.9	216
28	Automatic detection of subsolid pulmonary nodules in thoracic computed tomography images. Medical Image Analysis, 2014, 18, 374-384.	7.0	214
29	Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5-year screening interval. Thorax, 2017, 72, 48-56.	2.7	212
30	Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Annals of Internal Medicine, 2016, 164, 215.	2.0	209
31	Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA - Journal of the American Medical Association, 2018, 319, 154.	3.8	209
32	Characteristics of Lung Cancers Detected by Computer Tomography Screening in the Randomized NELSON Trial. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 848-854.	2.5	202
33	Breast cancer screening and cost-effectiveness; Policy alternatives, quality of life considerations and the possible impact of uncertain factors. International Journal of Cancer, 1991, 49, 531-537.	2.3	195
34	Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. European Respiratory Journal, 2013, 42, 1659-1667.	3.1	190
35	Health-Related Quality-of-Life Effects of Radical Prostatectomy and Primary Radiotherapy for Screen-Detected or Clinically Diagnosed Localized Prostate Cancer. Journal of Clinical Oncology, 2001, 19, 1619-1628.	0.8	187
36	Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial. Lancet Oncology, The, 2016, 17, 907-916.	5.1	183

#	Article	IF	CITATIONS
37	Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography. JAMA - Journal of the American Medical Association, 2021, 325, 988.	3.8	181
38	Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). European Urology, 2009, 56, 584-591.	0.9	180
39	Real-Time Monitoring of Results During First Year ofÂDutchÂColorectal Cancer Screening Program andÂOptimizationÂbyÂAltering Fecal Immunochemical TestÂCut-OffÂLevels. Gastroenterology, 2017, 152, 767-775.e2.	0.6	179
40	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	12.5	178
41	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	0.8	176
42	Benefits, Harms, and Cost-Effectiveness of Supplemental Ultrasonography Screening for Women With Dense Breasts. Annals of Internal Medicine, 2015, 162, 157-166.	2.0	175
43	Interpreting Overdiagnosis Estimates in Population-based Mammography Screening. Epidemiologic Reviews, 2011, 33, 111-121.	1.3	174
44	<i>BRCA1</i> -Associated Breast Cancers Present Differently From <i>BRCA2</i> -Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. Journal of Clinical Oncology, 2010, 28, 5265-5273.	0.8	166
45	Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. Annals of Internal Medicine, 2017, 167, 449.	2.0	160
46	Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. International Journal of Cancer, 2005, 116, 291-296.	2.3	158
47	Short-Term Effects of Population-Based Screening for Prostate Cancer on Health-Related Quality of Life. Journal of the National Cancer Institute, 1998, 90, 925-931.	3.0	146
48	Breast Cancer Screening Policies in Developing Countries: A Cost-effectiveness Analysis for India. Journal of the National Cancer Institute, 2008, 100, 1290-1300.	3.0	146
49	Coronary Artery Calcium Can Predict All-Cause Mortality and Cardiovascular Events on Low-Dose CT Screening for Lung Cancer. American Journal of Roentgenology, 2012, 198, 505-511.	1.0	146
50	Impact of Reduced Tobacco Smoking on Lung Cancer Mortality in the United States During 1975–2000. Journal of the National Cancer Institute, 2012, 104, 541-548.	3.0	145
51	Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial. International Journal of Cancer, 2002, 98, 268-273.	2.3	142
52	A model for breast cancer screening. Cancer, 1990, 66, 1601-1612.	2.0	139
53	Smooth or Attached Solid Indeterminate Nodules Detected at Baseline CT Screening in the NELSON Study: Cancer Risk during 1 Year of Follow-up. Radiology, 2009, 250, 264-272.	3.6	133
54	The prostate cancer conundrum revisited. Cancer, 2012, 118, 5955-5963.	2.0	125

#	Article	IF	CITATIONS
55	Identification of Chronic Obstructive Pulmonary Disease in Lung Cancer Screening Computed Tomographic Scans. JAMA - Journal of the American Medical Association, 2011, 306, 1775-81.	3.8	123
56	Personalizing Age of Cancer Screening Cessation Based on Comorbid Conditions: Model Estimates of Harms and Benefits. Annals of Internal Medicine, 2014, 161, 104.	2.0	123
57	Computer-aided Detection versus Independent Double Reading of Masses on Mammograms. Radiology, 2003, 227, 192-200.	3.6	122
58	Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening. Annals of Internal Medicine, 2016, 164, 205.	2.0	121
59	Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality. Journal of the National Cancer Institute, 2014, 106, .	3.0	120
60	Benefits, Harms, and Costs for Breast Cancer Screening After US Implementation of Digital Mammography. Journal of the National Cancer Institute, 2014, 106, dju092.	3.0	120
61	Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. European Journal of Cancer, 2020, 127, 207-223.	1.3	120
62	The impact of a breast cancer screening programme on quality-adjusted life-years. International Journal of Cancer, 1991, 49, 538-544.	2.3	119
63	Comparing coronary artery calcium and thoracic aorta calcium for prediction of all-cause mortality and cardiovascular events on low-dose non-gated computed tomography in a high-risk population of heavy smokers. Atherosclerosis, 2010, 209, 455-462.	0.4	117
64	Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Medicine, 2017, 14, e1002225.	3.9	114
65	MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 1136-1147.	5.1	112
66	Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer. European Urology, 2015, 68, 885-890.	0.9	111
67	The cost-effectiveness of breast cancer screening. International Journal of Cancer, 1989, 43, 1055-1060.	2.3	110
68	Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years. Annals of Internal Medicine, 2012, 156, 609.	2.0	110
69	Nation-wide breast cancer screening in The Netherlands: Results of initial and subsequent screening 1990–1995. , 1998, 75, 694-698.		108
70	Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). Cancer, 2008, 113, 396-404.	2.0	107
71	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	3.6	107
72	Nationwide breast cancer screening programme fully implemented in the Netherlands. Breast, 2001, 10, 6-11.	0.9	101

#	Article	IF	CITATIONS
73	Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. European Urology, 2013, 64, 530-539.	0.9	101
74	Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. European Journal of Cancer, 2020, 127, 224-235.	1.3	101
75	Genome-wide association study of coronary and aortic calcification implicates risk loci for coronary artery disease and myocardial infarction. Atherosclerosis, 2013, 228, 400-405.	0.4	100
76	ls prostate cancer different in black men? Answers from 3 natural history models. Cancer, 2017, 123, 2312-2319.	2.0	100
77	Psychosocial predictors of first attendance for organised mammography screening. Journal of Medical Screening, 1999, 6, 82-88.	1.1	99
78	Pulmonary Nodules Detected at Lung Cancer Screening: Interobserver Variability of Semiautomated Volume Measurements. Radiology, 2006, 241, 251-257.	3.6	99
79	Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?. European Respiratory Journal, 2015, 45, 765-773.	3.1	98
80	Mammography Screening and Risk of Breast Cancer Death: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 66-73.	1.1	94
81	European randomized lung cancer screening trials: Post NLST. Journal of Surgical Oncology, 2013, 108, 280-286.	0.8	94
82	Assessment of nationwide cancer-screening programmes. Lancet, The, 2000, 355, 80-81.	6.3	92
83	Two distinct groups of non-attenders in an organized mammography screening program. Breast Cancer Research and Treatment, 2001, 70, 145-153.	1.1	92
84	Effect of Recall Rate on Earlier Screen Detection of Breast Cancers Based on the Dutch Performance Indicators. Journal of the National Cancer Institute, 2005, 97, 748-754.	3.0	91
85	Automated Coronary Artery Calcification Scoring in Non-Gated Chest CT: Agreement and Reliability. PLoS ONE, 2014, 9, e91239.	1.1	90
86	Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Annals of Internal Medicine, 2016, 165, 700.	2.0	90
87	Lung Cancer Screening CT-Based Prediction of CardiovascularÂEvents. JACC: Cardiovascular Imaging, 2013, 6, 899-907.	2.3	89
88	MR Imaging as an Additional Screening Modality for the Detection of Breast Cancer in Women Aged 50–75 Years with Extremely Dense Breasts: The DENSE Trial Study Design. Radiology, 2015, 277, 527-537.	3.6	89
89	Effects of Systematic Screening and Detection of Child Abuse in Emergency Departments. Pediatrics, 2012, 130, 457-464.	1.0	88
90	Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Medicine, 2014, 12, 26.	2.3	88

Harry J De Koning

#	Article	IF	CITATIONS
91	Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer. Breast Cancer Research and Treatment, 2006, 100, 109-119.	1.1	83
92	Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. European Journal of Radiology, 2008, 68, 347-352.	1.2	82
93	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine, 2019, 171, 796.	2.0	81
94	Computed tomographic characteristics of interval and post screen carcinomas in lung cancer screening. European Radiology, 2015, 25, 81-88.	2.3	80
95	Differences in Natural History between Breast Cancers in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1458-1468.	1.1	79
96	Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referrals. European Radiology, 2013, 23, 1836-1845.	2.3	79
97	Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study. Gut, 2015, 64, 1584-1592.	6.1	79
98	Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology, 2004, 63, 309-313.	0.5	78
99	Survival benefit in women with <i>BRCA1</i> mutation or familial risk in the <scp>MRI</scp> screening study (<scp>MRISC</scp>). International Journal of Cancer, 2015, 137, 1729-1738.	2.3	78
100	Work at night and breast cancer – report on evidence-based options for preventive actions. Scandinavian Journal of Work, Environment and Health, 2012, 38, 380-390.	1.7	78
101	Screening for child abuse at emergency departments: a systematic review. Archives of Disease in Childhood, 2010, 95, 214-218.	1.0	77
102	Lung Cancer Detectability by Test, Histology, Stage, and Gender: Estimates from the NLST and the PLCO Trials. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 154-161.	1.1	77
103	Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). , 1999, 84, 437-441.		76
104	Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review. European Journal of Cancer, 2020, 127, 191-206.	1.3	76
105	Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. International Journal of Cancer, 2003, 105, 394-399.	2.3	75
106	Patients' perceptions of the side-effects of prostate cancer treatment—A qualitative interview study. Social Science and Medicine, 2006, 63, 911-919.	1.8	75
107	Effect of Nodule Characteristics on Variability of Semiautomated Volume Measurements in Pulmonary Nodules Detected in a Lung Cancer Screening Program. Radiology, 2008, 248, 625-631.	3.6	75
108	Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU International, 2003, 92, 71-78.	1.3	74

#	Article	IF	CITATIONS
109	Independent Double Reading of Screening Mammograms in the Netherlands: Effect of Arbitration Following Reader Disagreements. Radiology, 2004, 231, 564-570.	3.6	74
110	Hereditary breast cancer growth rates and its impact on screening policy. European Journal of Cancer, 2005, 41, 1610-1617.	1.3	74
111	Chapter 9: The MISCAN-Fadia Continuous Tumor Growth Model for Breast Cancer. Journal of the National Cancer Institute Monographs, 2006, 2006, 56-65.	0.9	74
112	Personalizing Colonoscopy Screening for Elderly Individuals Based on Screening History, Cancer Risk, and Comorbidity Status Could Increase Cost Effectiveness. Gastroenterology, 2015, 149, 1425-1437.	0.6	74
113	Nation-wide breast cancer screening in the Netherlands: Support for breast-cancer mortality reduction. International Journal of Cancer, 1995, 60, 777-780.	2.3	73
114	In search of the best upper age limit for breast cancer screening. European Journal of Cancer, 1995, 31, 2040-2043.	1.3	72
115	Magnetic Resonance Imaging Improves Breast Screening Sensitivity in <i>BRCA</i> Mutation Carriers Age ≥ 50 Years: Evidence From an Individual Patient Data Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 349-356.	0.8	72
116	Gleason score, age and screening: Modeling dedifferentiation in prostate cancer. International Journal of Cancer, 2006, 119, 2366-2371.	2.3	70
117	Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States. Annals of the American Thoracic Society, 2020, 17, 186-194.	1.5	70
118	Mammographic screening: evidence from randomised controlled trials. Annals of Oncology, 2003, 14, 1185-1189.	0.6	68
119	COMPARISON OF SCREEN DETECTED AND CLINICALLY DIAGNOSED PROSTATE CANCER IN THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, SECTION ROTTERDAM. Journal of Urology, 2005, 174, 121-125.	0.2	68
120	Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. Cancer, 2006, 106, 2318-2326.	2.0	68
121	Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. European Journal of Cancer, 2009, 45, 127-138.	1.3	68
122	A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. Journal of the National Cancer Institute, 2020, 112, 466-479.	3.0	67
123	Nation-wide data on screening performance during the transition to digital mammography: Observations in 6 million screens. European Journal of Cancer, 2013, 49, 3517-3525.	1.3	66
124	Accuracy of a screening instrument to identify potential child abuse in emergency departments. Child Abuse and Neglect, 2014, 38, 1275-1281.	1.3	66
125	Supplemental Breast MRI for Women with Extremely Dense Breasts: Results of the Second Screening Round of the DENSE Trial. Radiology, 2021, 299, 278-286.	3.6	66
126	Rotterdam AMblyopia Screening Effectiveness Study: Detection and Causes of Amblyopia in a Large Birth Cohort. , 2010, 51, 3476.		65

#	Article	IF	CITATIONS
127	Race-Specific Impact of Natural History, Mammography Screening, and Adjuvant Treatment on Breast Cancer Mortality Rates in the United States. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 112-122.	1.1	65
128	The effectiveness of a computer-tailored smoking cessation intervention for participants in lung cancer screening: A randomised controlled trial. Lung Cancer, 2012, 76, 204-210.	0.9	65
129	Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials. Cancer, 2014, 120, 1713-1724.	2.0	65
130	Health-related quality of life in patients with adolescent idiopathic scoliosis after treatment: short-term effects after brace or surgical treatment. European Spine Journal, 2007, 16, 83-89.	1.0	64
131	European Code against Cancer, 4th Edition: Cancer screening. Cancer Epidemiology, 2015, 39, S139-S152.	0.8	64
132	Lung cancer screening: latest developments and unanswered questions. Lancet Respiratory Medicine,the, 2016, 4, 749-761.	5.2	64
133	Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study. Lung Cancer, 2017, 113, 45-50.	0.9	64
134	European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam Pilot studies. Cancer, 1995, 76, 129-134.	2.0	63
135	Diagnosis of chronic obstructive pulmonary disease in lung cancer screening Computed Tomography scans: independent contribution of emphysema, air trapping and bronchial wall thickening. Respiratory Research, 2013, 14, 59.	1.4	63
136	Cost effectiveness of shortening screening interval or extending age range of NHS breast screening programme: computer simulation study. BMJ: British Medical Journal, 1998, 317, 376-379.	2.4	62
137	Improving cancer control in the European Union: Conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2007. European Journal of Cancer, 2008, 44, 1457-1462.	1.3	62
138	Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening. Thorax, 2018, 73, 779-781.	2.7	62
139	The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes and Control, 2012, 23, 827-835.	0.8	61
140	Extra incidence caused by mammographic screening. Lancet, The, 1994, 343, 979.	6.3	60
141	European randomized study of screening for prostate cancer—The Rotterdam pilot studies. , 1996, 65, 145-151.		59
142	Response shift due to diagnosis and primary treatment of localized prostate cancer: a then-test and a vignette study. Quality of Life Research, 2007, 16, 1627-1634.	1.5	59
143	Does "Normal―Aging Imply Urinary, Bowel, and Erectile Dysfunction? A General Population Survey. Urology, 2008, 72, 3-9.	O.5	58
144	Detection and quantification of the solid component in pulmonary subsolid nodules by semiautomatic segmentation. European Radiology, 2015, 25, 488-496.	2.3	58

#	Article	IF	CITATIONS
145	The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands. Gut, 2015, 64, 1985-1997.	6.1	58
146	Cost-Effectiveness of Screening Women With Familial Risk for Breast Cancer With Magnetic Resonance Imaging. Journal of the National Cancer Institute, 2013, 105, 1314-1321.	3.0	57
147	Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST). Health Policy, 2018, 122, 1190-1197.	1.4	57
148	Psychological distress in women at increased risk for breast cancer: the role of risk perception. European Journal of Cancer, 2004, 40, 2056-2063.	1.3	56
149	School-based Internet-tailored fruit and vegetable education combined with brief counselling increases children's awareness of intake levels. Public Health Nutrition, 2007, 10, 273-279.	1.1	56
150	Impressive timeâ€related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975â€2006. International Journal of Cancer, 2008, 123, 1929-1934.	2.3	56
151	Benefits and Harms of Mammography Screening After Age 74 Years: Model Estimates of Overdiagnosis. Journal of the National Cancer Institute, 2015, 107, djv103-djv103.	3.0	56
152	The efficacy of prostateâ€specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer, 2018, 124, 1197-1206.	2.0	56
153	Advanced breast cancer and its prevention by screening. British Journal of Cancer, 1992, 65, 950-955.	2.9	55
154	How cost-effective is breast cancer screening in different EC countries?. European Journal of Cancer, 1993, 29, 1663-1668.	1.3	55
155	A Cluster-Randomized Trial of Screening for Language Delay in Toddlers: Effects on School Performance and Language Development at Age 8. Pediatrics, 2007, 120, 1317-1325.	1.0	55
156	Detection of child abuse in emergency departments: a multi-centre study. Archives of Disease in Childhood, 2011, 96, 422-425.	1.0	55
157	The potential of breast cancer screening in Europe. International Journal of Cancer, 2021, 148, 406-418.	2.3	55
158	Multiethnic Exome-Wide Association Study of Subclinical Atherosclerosis. Circulation: Cardiovascular Genetics, 2016, 9, 511-520.	5.1	54
159	Risk stratification based on screening history: the NELSON lung cancer screening study. Thorax, 2017, 72, 819-824.	2.7	54
160	Lead-time in the European Randomised Study of Screening for Prostate Cancer. European Journal of Cancer, 2010, 46, 3102-3108.	1.3	53
161	Additional Double Reading of Screening Mammograms by Radiologic Technologists: Impact on Screening Performance Parameters. Journal of the National Cancer Institute, 2007, 99, 1162-1170.	3.0	52
162	Quantification of coronary artery calcium in nongated CT to predict cardiovascular events in male lung cancer screening participants: Results of the NELSON study. Journal of Cardiovascular Computed Tomography, 2015, 9, 50-57.	0.7	52

#	Article	IF	CITATIONS
163	The effect of populationâ€based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of followâ€up. International Journal of Cancer, 2017, 141, 671-677.	2.3	52
164	Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam. Journal of the National Cancer Institute, 2010, 102, 352-355.	3.0	51
165	The Role of Conventional Bronchoscopy in the Workup of Suspicious CT Scan Screen-Detected Pulmonary Nodules. Chest, 2012, 142, 377-384.	0.4	51
166	Internet Versus Paper Mode of Health and Health Behavior Questionnaires in Elementary Schools: Asthma and Fruit as Examples. Journal of School Health, 2006, 76, 80-86.	0.8	50
167	Airway wall thickness associated with forced expiratory volume in 1 second decline and development of airflow limitation. European Respiratory Journal, 2015, 45, 644-651.	3.1	50
168	Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe. Cancers, 2020, 12, 1672.	1.7	50
169	Mammography benefit in the Canadian National Breast Screening Study-2: A model evaluation. International Journal of Cancer, 2004, 110, 756-762.	2.3	49
170	Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking—A modelling study. Lung Cancer, 2018, 121, 61-69.	0.9	49
171	Costâ€effectiveness of mammographic screening in Australia. Australian Journal of Public Health, 1993, 17, 42-50.	0.2	48
172	Breast cancer screening: its impact on clinical medicine. British Journal of Cancer, 1990, 61, 292-297.	2.9	45
173	How to deal with incidentally detected pulmonary nodules less than 10mm in size on CT in a healthy person. Lung Cancer, 2008, 60, 151-159.	0.9	45
174	Digital mammography screening: Weighing reduced mortality against increased overdiagnosis. Preventive Medicine, 2011, 53, 134-140.	1.6	45
175	Genome-wide study identifies two loci associated with lung function decline in mild to moderate COPD. Human Genetics, 2013, 132, 79-90.	1.8	45
176	Lung cancer screening by low-dose spiral computed tomography. European Respiratory Journal, 2001, 18, 857-866.	3.1	44
177	What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 740-750.	1.1	43
178	Facilitators and barriers to screening for child abuse in the emergency department. BMC Pediatrics, 2012, 12, 167.	0.7	43
179	Sexual function with localized prostate cancer: active surveillance vs radical therapy. BJU International, 2012, 110, 1032-1039.	1.3	43
180	The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index. Value in Health, 2016, 19, 153-157.	0.1	43

#	Article	IF	CITATIONS
181	Screening for cardiovascular disease risk using traditional risk factor assessment or coronary artery calcium scoring: the ROBINSCA trial. European Heart Journal Cardiovascular Imaging, 2020, 21, 1216-1224.	0.5	43
182	Prediction of the effects and costs of breast-cancer screening in Germany. International Journal of Cancer, 1994, 58, 623-628.	2.3	42
183	Overdiagnosis and overtreatment of breast cancer: Microsimulation modelling estimates based on observed screen and clinical data. Breast Cancer Research, 2005, 8, 202.	2.2	42
184	Seventy-five years is an appropriate upper age limit for population-based mammography screening. International Journal of Cancer, 2006, 118, 2020-2025.	2.3	42
185	New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial. Journal of Thoracic Oncology, 2018, 13, 1410-1414.	0.5	42
186	Effectiveness of screening for amblyopia and other eye disorders in a prospective birth cohort study. Journal of Medical Screening, 2013, 20, 66-72.	1.1	40
187	Evaluation of prostateâ€specific antigen, digital rectal examination and transrectal ultrasonography in populationâ€based screening for prostate cancer: improving the efficiency of early detection. British Journal of Urology, 1997, 79, 57-63.	0.1	39
188	PROSTATE SPECIFIC ANTIGEN TESTING AND DIGITAL RECTAL EXAMINATION BEFORE AND DURING A RANDOMIZED TRIAL OF SCREENING FOR PROSTATE CANCER: EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER, ROTTERDAM. Journal of Urology, 2000, 164, 1216-1220.	0.2	39
189	Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate, 2001, 46, 87-97.	1.2	39
190	Contribution of CT Quantified Emphysema, Air Trapping and Airway Wall Thickness on Pulmonary Function in Male Smokers With and Without COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 503-509.	0.7	39
191	Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study. Lung Cancer, 2018, 125, 103-108.	0.9	39
192	Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue. Journal of the National Cancer Institute, 2021, 113, 1476-1483.	3.0	39
193	Lung cancer screening by spiral CT. What is the optimal target population for screening trials?. Lung Cancer, 2002, 38, 243-252.	0.9	38
194	Passive coping and psychological distress in women adhering to regular breast cancer surveillance. Psycho-Oncology, 2007, 16, 851-858.	1.0	38
195	Comparing Benefits from Many Possible Computed Tomography Lung Cancer Screening Programs: Extrapolating from the National Lung Screening Trial Using Comparative Modeling. PLoS ONE, 2014, 9, e99978.	1.1	38
196	Prostate cancer diagnosis: The impact on patients' mental health. European Journal of Cancer, 2006, 42, 165-170.	1.3	37
197	A decade of breast cancer screening in The Netherlands: trends in the preoperative diagnosis of breast cancer. Breast Cancer Research and Treatment, 2007, 106, 113-119.	1.1	37
198	High affective risk perception is associated with more lung cancer-specific distress in CT screening for lung cancer. Lung Cancer, 2008, 62, 385-390.	0.9	37

#	Article	IF	CITATIONS
199	Delayed diagnosis of breast cancer in women recalled for suspicious screening mammography. European Journal of Cancer, 2009, 45, 774-781.	1.3	37
200	The effects of populationâ€based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy. International Journal of Cancer, 2015, 137, 165-172.	2.3	37
201	An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. Gastroenterology, 2015, 149, 577-585.e4.	0.6	37
202	Stage distribution of screen-detected colorectal cancers in the Netherlands. Gut, 2018, 67, 1745-1746.	6.1	37
203	Feasibility, acceptability, and quality of Internet-administered adolescent health promotion in a preventive-care setting. Health Education Research, 2006, 22, 1-13.	1.0	36
204	An Educational Cartoon Accelerates Amblyopia Therapy and Improves Compliance, Especially among Children of Immigrants. Ophthalmology, 2012, 119, 2393-2401.	2.5	36
205	Do women make an informed choice about participating in breast cancer screening? A survey among women invited for a first mammography screening examination. Patient Education and Counseling, 2012, 89, 353-359.	1.0	36
206	Association of Chronic Obstructive Pulmonary Disease and Smoking Status With Bone Density and Vertebral Fractures in Male Lung Cancer Screening Participants. Journal of Bone and Mineral Research, 2014, 29, 2224-2229.	3.1	36
207	The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. International Journal of Cancer, 2017, 140, 2436-2443.	2.3	36
208	Coronary Artery Calcium Imaging in the ROBINSCA Trial. Academic Radiology, 2018, 25, 118-128.	1.3	36
209	Cost-effectiveness of High-performance Biomarker TestsÂvsÂFecal Immunochemical Test for Noninvasive ColorectalÂCancer Screening. Clinical Gastroenterology and Hepatology, 2018, 16, 504-512.e11.	2.4	36
210	Personalising lung cancer screening: An overview of riskâ€stratification opportunities and challenges. International Journal of Cancer, 2021, 149, 250-263.	2.3	36
211	Breast Cancer Screening Strategies for Women With <i>ATM, CHEK2</i> , and <i>PALB2</i> Pathogenic Variants. JAMA Oncology, 2022, 8, 587.	3.4	36
212	Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revisited?. BJU International, 2003, 92, 101-105.	1.3	35
213	Ethnic differences in participation in prenatal screening for Down syndrome: A registerâ€based study. Prenatal Diagnosis, 2010, 30, 988-994.	1.1	35
214	The impact on socio-emotional development and quality of life of language impairment in 8-year-old children. Developmental Medicine and Child Neurology, 2011, 53, 81-88.	1.1	35
215	How Does Early Detection by Screening Affect Disease Progression?. Medical Decision Making, 2011, 31, 550-558.	1.2	35
216	Which strategies reduce breast cancer mortality most?. Cancer, 2013, 119, 2541-2548.	2.0	35

#	Article	IF	CITATIONS
217	Costâ€effectiveness of digital mammography screening before the age of 50 in <scp>T</scp> he <scp>N</scp> etherlands. International Journal of Cancer, 2015, 137, 1990-1999.	2.3	35
218	Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study. Thorax, 2018, 73, 741-747.	2.7	35
219	Role of baseline nodule density and changes in density and nodule features in the discrimination between benign and malignant solid indeterminate pulmonary nodules. European Journal of Radiology, 2009, 70, 492-498.	1.2	34
220	Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening Study. Journal of Thoracic Oncology, 2015, 10, 747-753.	0.5	34
221	Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History. Journal of the National Cancer Institute, 2021, 113, 434-442.	3.0	34
222	Breast cancer screening; cost-effective in practice?. European Journal of Radiology, 2000, 33, 32-37.	1.2	33
223	A cluster-randomised trial of screening for language disorders in toddlers. Journal of Medical Screening, 2004, 11, 109-116.	1.1	33
224	Patients' Preferences for Scoliosis Brace Treatment. Spine, 2010, 35, 57-63.	1.0	33
225	Lung cancer screening and smoking cessation efforts. Translational Lung Cancer Research, 2021, 10, 1099-1109.	1.3	33
226	Estimating the Effectiveness of Screening for Scoliosis: A Case-Control Study. Pediatrics, 2008, 121, 9-14.	1.0	32
227	Informed decision-making in prenatal screening for Down's syndrome: What knowledge is relevant?. Patient Education and Counseling, 2011, 84, 265-270.	1.0	32
228	Novel Genes for Airway Wall Thickness Identified with Combined Genome-Wide Association and Expression Analyses. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 547-556.	2.5	32
229	Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. European Journal of Cancer, 2017, 85, 31-38.	1.3	32
230	Costâ€effectiveness of HPVâ€based cervical screening based on first year results in the Netherlands: a modelling study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 573-582.	1.1	32
231	Rate of progression of CT-quantified emphysema in male current and ex-smokers: a follow-up study. Respiratory Research, 2013, 14, 55.	1.4	31
232	Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?. Journal of Thoracic Oncology, 2015, 10, 1285-1291.	0.5	31
233	Overdiagnosis in lung cancer screening: why modelling is essential. Journal of Epidemiology and Community Health, 2015, 69, 1035-1039.	2.0	31
234	Biochemical verification of the self-reported smoking status of screened male smokers of the Dutch–Belgian randomized controlled lung cancer screening trial. Lung Cancer, 2016, 94, 96-101.	0.9	31

#	Article	IF	CITATIONS
235	Quantification of growth patterns of screen-detected lung cancers: The NELSON study. Lung Cancer, 2017, 108, 48-54.	0.9	31
236	Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models. Medical Decision Making, 2018, 38, 3S-8S.	1.2	31
237	Influence of lung nodule margin on volume- and diameter-based reader variability in CT lung cancer screening. British Journal of Radiology, 2018, 91, 20170405.	1.0	31
238	Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk. JAMA Oncology, 2020, 6, 1381.	3.4	31
239	Measuring disease specific quality of life in localized prostate cancer: the Dutch experience. Quality of Life Research, 2003, 12, 459-464.	1.5	30
240	Women's acceptance of MRI in breast cancer surveillance because of a familial or genetic predisposition. Breast, 2006, 15, 673-676.	0.9	30
241	Advanced prostate cancer: Course, care, and cost implications. , 1999, 40, 97-104.		29
242	Does participation to screening unintentionally influence lifestyle behaviour and thus lifestyle-related morbidity?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 465-478.	1.0	29
243	Pregnancy and liver adenoma management: PALM-study. BMC Gastroenterology, 2012, 12, 82.	0.8	29
244	Summary statement on screening for prostate cancer in Europe. International Journal of Cancer, 2018, 142, 741-746.	2.3	29
245	The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cutâ€off level on yield of screening. International Journal of Cancer, 2020, 147, 1098-1106.	2.3	29
246	Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncology, 2021, 7, 1833.	3.4	29
247	The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancer. Breast Cancer Research and Treatment, 2005, 89, 75-80.	1.1	28
248	Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer. European Journal of Cancer, 2005, 41, 1416-1425.	1.3	28
249	Parametric Response Mapping Adds Value to Current Computed Tomography Biomarkers in Diagnosing Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1084-1086.	2.5	28
250	Diagnosing non-palpable breast disease: short-term impact on quality of life of large-core needle biopsy versus open breast biopsy. Surgical Oncology, 2002, 10, 177-181.	0.8	27
251	Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam. European Urology, 2007, 51, 366-374.	0.9	27
252	Introduction of additional double reading of mammograms by radiographers: Effects on a biennial screening programme outcome. European Journal of Cancer, 2008, 44, 1223-1228.	1.3	27

#	Article	IF	CITATIONS
253	No Benefit for Consensus Double Reading at Baseline Screening for Lung Cancer with the Use of Semiautomated Volumetry Software. Radiology, 2012, 262, 320-326.	3.6	27
254	The provision of information and informed decision-making on prenatal screening for Down syndrome: A questionnaire- and register-based survey in a non-selected population. Patient Education and Counseling, 2012, 87, 351-359.	1.0	27
255	All ause mortality versus cancerâ€specific mortality as outcome in cancer screening trials: A review and modeling study. Cancer Medicine, 2019, 8, 6127-6138.	1.3	27
256	Discriminating dominant computed tomography phenotypes in smokers without or with mild COPD. Respiratory Medicine, 2014, 108, 136-143.	1.3	26
257	Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality. Breast Cancer Research and Treatment, 2012, 136, 823-835.	1.1	25
258	Semi-Automatic Quantification of Subsolid Pulmonary Nodules: Comparison with Manual Measurements. PLoS ONE, 2013, 8, e80249.	1.1	25
259	Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia. Medical Decision Making, 2018, 38, 54S-65S.	1.2	25
260	Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study. PLoS ONE, 2014, 9, e91621.	1.1	25
261	MISCAN: estimating lead-time and over-detection by simulation. BJU International, 2003, 92, 106-111.	1.3	24
262	Health-related Quality of Life in Preschool Children with Wheezing and Dyspnea: Preliminary Results from a Random General Population Sample. Quality of Life Research, 2005, 14, 1931-1936.	1.5	24
263	Breast cancer screening halves the risk of breast cancer death: A case-referent study. Breast, 2014, 23, 439-444.	0.9	24
264	Overdiagnosis by mammographic screening for breast cancer studied in birth cohorts in The Netherlands. International Journal of Cancer, 2015, 137, 921-929.	2.3	24
265	Interscan variation of semi-automated volumetry of subsolid pulmonary nodules. European Radiology, 2015, 25, 1040-1047.	2.3	24
266	Impact of a cardiovascular disease risk screening result on preventive behaviour in asymptomatic participants of the ROBINSCA trial. European Journal of Preventive Cardiology, 2019, 26, 1313-1322.	0.8	24
267	Cost-effectiveness of different reading and referral strategies in mammography screening in the Netherlands. Breast Cancer Research and Treatment, 2007, 102, 211-218.	1.1	23
268	Bracing Patients with Idiopathic Scoliosis: Design of the Dutch Randomized Controlled Treatment Trial. BMC Musculoskeletal Disorders, 2008, 9, 57.	0.8	23
269	A randomised controlled trial on the effectiveness of bracing patients with idiopathic scoliosis: failure to include patients and lessons to be learnt. European Spine Journal, 2010, 19, 747-753.	1.0	23
270	The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. Journal of Thoracic Oncology, 2014, 9, 141-143.	0.5	23

#	Article	IF	CITATIONS
271	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. Cancer, 2016, 122, 3386-3393.	2.0	23
272	Growth of hepatocellular adenoma during pregnancy: A prospective study. Journal of Hepatology, 2020, 72, 119-124.	1.8	23
273	Quality of life of children with language delays. Quality of Life Research, 2005, 14, 1345-1355.	1.5	22
274	Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls?. BJU International, 2007, 99, 801-806.	1.3	22
275	The Role of the (18)F-Fluorodeoxyglucose-Positron Emission Tomography Scan in the Nederlands Leuvens Longkanker Screenings Onderzoek Lung Cancer Screening Trial. Journal of Thoracic Oncology, 2011, 6, 1704-1712.	0.5	22
276	Screening for prostate cancer in the US? Reduce the harms and keep the benefit. International Journal of Cancer, 2015, 136, 1600-1607.	2.3	22
277	Bone density loss on computed tomography at 3-year follow-up in current compared to former male smokers. European Journal of Radiology, 2017, 89, 177-181.	1.2	22
278	Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model. BMC Cancer, 2018, 18, 464.	1.1	22
279	Modeling the natural history of ductal carcinoma in situ based on population data. Breast Cancer Research, 2020, 22, 53.	2.2	22
280	Changes in use of breast-conserving therapy in years 1978-2000. British Journal of Cancer, 1994, 70, 1165-1170.	2.9	21
281	Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round. , 1997, 73, 464-469.		21
282	Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial. European Journal of Cancer, 2001, 37, 2154-2160.	1.3	21
283	Low-dose computed tomography screening for lung cancer: results of the first screening round. Journal of Comparative Effectiveness Research, 2013, 2, 433-436.	0.6	21
284	DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2â€years. Journal of Clinical Pathology, 2017, 70, 250-254.	1.0	21
285	Assessment of harms, benefits, and costâ€effectiveness of prostate cancer screening: A microâ€simulation study of 230 scenarios. Cancer Medicine, 2020, 9, 7742-7750.	1.3	21
286	A longer breast carcinoma screening interval for women age older than 65 years?. , 1999, 86, 1506-1510.		20
287	Screening for scoliosis: do we have indications for effectiveness?. Journal of Medical Screening, 2006, 13, 29-33.	1.1	20
288	Modeling the impact of population screening on breast cancer mortality in the United States. Breast, 2011, 20, S75-S81.	0.9	20

#	Article	IF	CITATIONS
289	Generalisability of the results of the Dutch–Belgian randomised controlled lung cancer CT screening trial (NELSON): Does self-selection play a role?. Lung Cancer, 2012, 77, 51-57.	0.9	20
290	Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening. BMC Cancer, 2018, 18, 256.	1.1	20
291	Implementation of lung cancer screening: what are the main issues?. Translational Lung Cancer Research, 2021, 10, 1050-1063.	1.3	20
292	Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial. BMC Cancer, 2012, 12, 440.	1.1	19
293	Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD. European Respiratory Journal, 2015, 45, 60-75.	3.1	19
294	Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches. Medical Decision Making, 2018, 38, 126S-139S.	1.2	19
295	Treatment capacity required for fullâ€scale implementation of lung cancer screening in the United States. Cancer, 2019, 125, 2039-2048.	2.0	19
296	Have Preferences of Girls Changed Almost 3 Years after the Much Debated Start of the HPV Vaccination Program in the Netherlands? A Discrete Choice Experiment. PLoS ONE, 2014, 9, e104772.	1.1	19
297	A model-based prediction of the impact on reduction in mortality by a breast cancer screening programme in the city of Florence, Italy. European Journal of Cancer, 1995, 31, 348-353.	1.3	18
298	Disease-specific mortality may underestimate the total effect of prostate cancer screening. Journal of Medical Screening, 2010, 17, 204-210.	1.1	18
299	PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer. European Journal of Cancer, 2010, 46, 3053-3060.	1.3	18
300	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	1.1	18
301	Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study. Thorax, 2019, 74, 247-253.	2.7	18
302	Breast cancer screening: Evidence for false reassurance?. International Journal of Cancer, 2008, 123, 680-686.	2.3	17
303	Informed decision making does not affect health-related quality of life in lung cancer screening (NELSON trial). European Journal of Cancer, 2010, 46, 3300-3306.	1.3	17
304	Determinants and outcome of unsuccessful referral after positive screening in a large birth-cohort study of population-based vision screening. Journal of AAPOS, 2011, 15, 256-262.	0.2	17
305	Serum Lipid Levels, Body Mass Index, and Their Role in Coronary Artery Calcification. Circulation: Cardiovascular Genetics, 2015, 8, 327-333.	5.1	17
306	Transition From Film to Digital Mammography. American Journal of Preventive Medicine, 2015, 48, 535-542.	1.6	17

#	Article	IF	CITATIONS
307	Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models. European Journal of Cancer, 2016, 63, 135-142.	1.3	17
308	Should we start population screening for prostate cancer? Randomised trials are still needed. International Journal of Cancer, 2002, 97, 377-378.	2.3	16
309	Clinically detected non-aggressive lung cancers: implications for overdiagnosis and overtreatment in lung cancer screening. Thorax, 2018, 73, 407-408.	2.7	16
310	The influence of health systems on breast, cervical and colorectal cancer screening: an overview of systematic reviews using health systems and implementation research frameworks. Journal of Health Services Research and Policy, 2020, 25, 49-58.	0.8	16
311	Systematic Review and Meta-Analysis of Community- and Choice-Based Health State Utility Values for Lung Cancer. Pharmacoeconomics, 2020, 38, 1187-1200.	1.7	16
312	Monitoring the ERSPC trial. BJU International, 2003, 92, 112-114.	1.3	15
313	Risk of Cardiovascular Mortality in Prostate Cancer Patients in the Rotterdam Randomized Screening Trial. Journal of Clinical Oncology, 2006, 24, 4184-4189.	0.8	15
314	Health-Related Quality of Life in Adolescents with Wheezing Attacks. Journal of Adolescent Health, 2007, 41, 464-471.	1.2	15
315	Utilization and cost of diagnostic imaging and biopsies following positive screening mammography in the southern breast cancer screening region of the Netherlands, 2000–2005. European Radiology, 2008, 18, 2390-2397.	2.3	15
316	Blinded and uniform cause of death verification in a lung cancer CT screening trial. Lung Cancer, 2012, 77, 522-525.	0.9	15
317	Prognostic value of heart valve calcifications for cardiovascular events in a lung cancer screening population. International Journal of Cardiovascular Imaging, 2015, 31, 1243-1249.	0.7	15
318	Cost-effectiveness of Digital Breast Tomosynthesis in Population-based Breast Cancer Screening: A Probabilistic Sensitivity Analysis. Radiology, 2020, 297, 40-48.	3.6	15
319	Risk stratification in breast cancer screening: Costâ€effectiveness and harmâ€benefit ratios for lowâ€risk and highâ€risk women. International Journal of Cancer, 2020, 147, 3059-3067.	2.3	15
320	Life expectancy of screenâ€detected invasive breast cancer patients compared with women invited to the Nijmegen screening program. Cancer, 2010, 116, 586-591.	2.0	14
321	A comparison of parentâ€reported wheezing or shortness of breath among infants as assessed by questionnaire and physicianâ€interview: The Generation R study. Pediatric Pulmonology, 2010, 45, 500-507.	1.0	14
322	Blinded and uniform causes of death verification in cancer screening: A major influence on the outcome of a prostate cancer screening trial?. European Journal of Cancer, 2010, 46, 3061-3067.	1.3	14
323	<i>Chapter 7</i> : Description of MISCAN‣ung, the Erasmus MC Lung Cancer Microsimulation Model for Evaluating Cancer Control Interventions. Risk Analysis, 2012, 32, S85-98.	1.5	14
324	Likelihood of early detection of breast cancer in relation to false-positive risk in life-time mammographic screening: population-based cohort study. Annals of Oncology, 2013, 24, 2501-2506.	0.6	14

#	Article	IF	CITATIONS
325	Computed Tomography Structural Lung Changes in Discordant Airflow Limitation. PLoS ONE, 2013, 8, e65177.	1.1	14
326	Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1328-1336.	1.1	14
327	Peptides from the Variable Region of Specific Antibodies Are Shared among Lung Cancer Patients. PLoS ONE, 2014, 9, e96029.	1.1	14
328	The value of current diagnostic tests in prostate cancer screening. BJU International, 2001, 88, 458-466.	1.3	13
329	Screening for type 2 diabetes in a high-risk population: study design and feasibility of a population-based randomized controlled trial. BMC Public Health, 2012, 12, 671.	1.2	13
330	Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study. BJU International, 2017, 119, 560-566.	1.3	13
331	Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Medical Decision Making, 2018, 38, 140S-150S.	1.2	13
332	Costâ€effectiveness of surveillance schedules in older adults with nonâ€muscleâ€invasive bladder cancer. BJU International, 2019, 123, 307-312.	1.3	13
333	Selection of eligible participants for screening for lung cancer using primary care data. Thorax, 2022, 77, 882-890.	2.7	13
334	The importance of screening for lung cancer. Expert Review of Respiratory Medicine, 2014, 8, 597-614.	1.0	12
335	Developing a score chart to improve risk stratification of patients with colorectal adenoma. Endoscopy, 2016, 48, 563-570.	1.0	12
336	Effect of screening mammography on breast cancer mortality: Quasiâ€experimental evidence from rollout of the Dutch populationâ€based program with 17â€year followâ€up of a cohort. International Journal of Cancer, 2020, 146, 2201-2208.	2.3	12
337	Colonoscopy-Related Mortality in a Fecal Immunochemical Test–Based Colorectal Cancer Screening Program. Clinical Gastroenterology and Hepatology, 2021, 19, 1418-1425.	2.4	12
338	Rotterdam Randomized Pilot Studies of Screening for Prostate Cancer—An Overview After 10 Years. Journal of the National Cancer Institute, 2005, 97, 696-696.	3.0	11
339	Limited contamination in the Dutch–Belgian randomized lung cancer screening trial (NELSON). Lung Cancer, 2010, 69, 66-70.	0.9	11
340	Informing on prenatal screening for Down syndrome prior to conception. An empirical and ethical perspective. American Journal of Medical Genetics, Part A, 2012, 158A, 485-497.	0.7	11
341	Diffuse Idiopathic Skeletal Hyperostosis Is Associated with Lower Lung Volumes in Current and Former Smokers. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 241-242.	2.5	11
342	When should active surveillance for prostate cancer stop if no progression is detected?. Prostate, 2017, 77, 962-969.	1.2	11

#	Article	IF	CITATIONS
343	Impact of cause of death adjudication on the results of the European prostate cancer screening trial. British Journal of Cancer, 2017, 116, 141-148.	2.9	11
344	Costâ€effectiveness of the Norwegian breast cancer screening program. International Journal of Cancer, 2017, 140, 833-840.	2.3	11
345	Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology. Medical Decision Making, 2018, 38, 112S-125S.	1.2	11
346	Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries. Health Policy, 2018, 122, 1206-1211.	1.4	11
347	Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary. Journal of Medical Screening, 2021, 28, 268-276.	1.1	11
348	Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing. PLoS ONE, 2022, 17, e0264067.	1.1	11
349	Finding the optimal mammography screening strategy: A costâ€effectiveness analysis of 920 modelled strategies. International Journal of Cancer, 2022, 151, 287-296.	2.3	11
350	Test Sensitivity in the European Prostate Cancer Screening Trial: Results from Finland, Sweden, and the Netherlands. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2000-2005.	1.1	10
351	Early detection and counselling intervention of asthma symptoms in preschool children: study design of a cluster randomised controlled trial. BMC Public Health, 2010, 10, 555.	1.2	10
352	Disease-Specific Survival of Men With Prostate Cancer Detected During the Screening Interval: Results of the European Randomized Study of Screening for Prostate Cancer–Rotterdam After 11 Years of Follow-Up. European Urology, 2011, 60, 330-336.	0.9	10
353	Asthma-like symptoms in the first year of life and health-related quality of life at age 12Âmonths: the Generation R study. Quality of Life Research, 2012, 21, 545-554.	1.5	10
354	High-pitch versus sequential mode for coronary calcium in individuals with a high heart rate: Potential for dose reduction. Journal of Cardiovascular Computed Tomography, 2018, 12, 298-304.	0.7	10
355	Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results. Medical Decision Making, 2018, 38, 917-929.	1.2	10
356	Key indicators of organized cancer screening programs: Results from a Delphi study. Journal of Medical Screening, 2019, 26, 120-126.	1.1	10
357	Mammography requests in general practice during the introduction of nationwide breast cancer screening, 1988–1995. European Journal of Cancer, 1999, 35, 450-454.	1.3	9
358	Pulmonary function and CT biomarkers as risk factors for cardiovascular events in male lung cancer screening participants: the NELSON study. European Radiology, 2015, 25, 65-71.	2.3	9
359	Calibrating Parameters for Microsimulation Disease Models. Medical Decision Making, 2016, 36, 652-665.	1.2	9
360	A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries. Health Policy, 2018, 122, 1198-1205.	1.4	9

#	Article	IF	CITATIONS
361	Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators. Medical Decision Making, 2019, 39, 405-413.	1.2	9
362	Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates. Lung Cancer, 2020, 139, 200-206.	0.9	9
363	Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women. Journal of the National Cancer Institute, 2021, 113, 1017-1026.	3.0	9
364	Impact of Cardiovascular Calcifications on the Detrimental Effect of Continued Smoking on Cardiovascular Risk in Male Lung Cancer Screening Participants. PLoS ONE, 2013, 8, e66484.	1.1	8
365	Follow-up of CT-derived airway wall thickness: Correcting for changes in inspiration level improves reliability. European Journal of Radiology, 2016, 85, 2008-2013.	1.2	8
366	Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age. MDM Policy and Practice, 2017, 2, 238146831771798.	0.5	8
367	The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers. European Urology, 2019, 76, 276-279.	0.9	8
368	Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk. Breast, 2021, 56, 1-6.	0.9	8
369	Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. Journal of Medical Screening, 2013, 20, 33-38.	1.1	8
370	The Early Detection of Breast Cancer Using Liquid Biopsies: Model Estimates of the Benefits, Harms, and Costs. Cancers, 2022, 14, 2951.	1.7	8
371	Trends in mammography 1991–96 and the impact of nationwide screening in the Netherlands. Journal of Medical Screening, 1999, 6, 94-98.	1.1	7
372	Update on screening and early detection of prostate cancer. Current Opinion in Urology, 2004, 14, 151-156.	0.9	7
373	Screening for Type 2 Diabetes in a High-Risk Population: Effects of a Negative Screening Test After 4ÂYears Follow-up. Annals of Behavioral Medicine, 2014, 47, 102-110.	1.7	7
374	The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. PLoS ONE, 2018, 13, e0202924.	1.1	7
375	Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program. Clinical Chemistry, 2019, 65, 419-426.	1.5	7
376	Plusoptix photoscreener use for paediatric vision screening in Flanders and Iran. Acta Ophthalmologica, 2020, 98, 80-88.	0.6	7
377	The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe. Preventive Medicine Reports, 2021, 22, 101392.	0.8	7
378	Anticipating the Consequences for the Primary Therapy of Breast Cancer after Introducing Screening: A More Clobal Picture for Health Care Policy Making. International Journal of Technology Assessment in Health Care, 1998, 14, 268-276.	0.2	6

#	Article	IF	CITATIONS
379	Costs and effects of ultrasonography in the evaluation of palpable breast masses. International Journal of Technology Assessment in Health Care, 2004, 20, 440-448.	0.2	6
380	Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screenâ€detection in older (65+) men. International Journal of Cancer, 2016, 138, 2522-2528.	2.3	6
381	The role of pre-invasive disease in overdiagnosis: A microsimulation study comparing mass screening for breast cancer and cervical cancer. Journal of Medical Screening, 2016, 23, 210-216.	1.1	6
382	Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance. Cancer, 2018, 124, 507-513.	2.0	6
383	Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study. Journal of General Internal Medicine, 2019, 34, 2374-2381.	1.3	6
384	Uptake of minimally invasive surgery and stereotactic body radiation therapy for early stage non-small cell lung cancer in the USA: an ecological study of secular trends using the National Cancer Database. BMJ Open Respiratory Research, 2020, 7, e000603.	1.2	6
385	Screening for coronary artery calcium in a high-risk population: the ROBINSCA trial. European Journal of Preventive Cardiology, 2021, 28, 1155-1159.	0.8	6
386	Screening for cancers with a good prognosis: The case of testicular germ cell cancer. Cancer Medicine, 2021, 10, 2897-2903.	1.3	6
387	Extending Age Ranges in Breast Cancer Screening in Four European Countries: Model Estimations of Harm-to-Benefit Ratios. Cancers, 2021, 13, 3360.	1.7	6
388	Optimizing screening with faecal immunochemical test for both sexes - Cost-effectiveness analysis from Finland. Preventive Medicine, 2022, 157, 106990.	1.6	6
389	1213 COST-EFFECTIVENESS OF PROSTATE CANCER SCREENING BASED ON THE EUROPEAN RANDOMISED STUDY OF SCREENING FOR PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.2	5
390	Swiss Medical Board Mammography screening predictions for Switzerland: Importance of time-periods. Journal of Medical Screening, 2015, 22, 201-206.	1.1	5
391	Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status. Cancer Immunology Research, 2016, 4, 165-172.	1.6	5
392	Breast cancer incidence trends in Norway and estimates of overdiagnosis. Journal of Medical Screening, 2017, 24, 83-91.	1.1	5
393	EU Policy on Lung Cancer CT Screening 2017. Biomedicine Hub, 2017, 2, 1-8.	0.4	5
394	The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia. Gynecologic Oncology, 2021, 160, 118-127.	0.6	5
395	Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening. Value in Health, 2021, 24, 353-360.	0.1	5
396	Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline–Noncompliant Women. JAMA Oncology, 2021, 7, 885.	3.4	5

#	Article	IF	CITATIONS
397	Editorial: Social Inequality in Cancer Screening. Frontiers in Public Health, 2022, 10, 854659.	1.3	5
398	A Comparison of Disease Specific Survival of Patients Who Died of and Who Had Newly Diagnosed Prostate Cancer. Journal of Urology, 1997, 157, 1768-1772.	0.2	4
399	The Norwegian decision on screening for prostate cancer: a response. Lancet Oncology, The, 2001, 2, 746-749.	5.1	4
400	Uniform and blinded cause of death verification of the NELSON lung cancer screening participants. Lung Cancer, 2017, 111, 131-134.	0.9	4
401	Response to the letter commenting on ʻEffect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review'. European Journal of Cancer, 2020, 138, 232-233.	1.3	4
402	The comparative effectiveness of mpMRI and MRI-guided biopsy vs regular biopsy in a population-based PSA testing: a modeling study. Scientific Reports, 2021, 11, 1801.	1.6	4
403	Costâ€effectiveness of multiparametric magnetic resonance imaging and MRIâ€guided biopsy in a populationâ€based prostate cancer screening setting using a microâ€simulation model. Cancer Medicine, 2021, 10, 4046-4053.	1.3	4
404	Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration. PLoS ONE, 2021, 16, e0253893.	1.1	4
405	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe. MDM Policy and Practice, 2021, 6, 238146832098497.	0.5	4
406	The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening. Public Health Research and Practice, 2019, 29, .	0.7	4
407	Early detection of obstructive coronary artery disease in the asymptomatic high-risk population: objectives and study design of the EARLY-SYNERGY trial. American Heart Journal, 2022, 246, 166-177.	1.2	4
408	Why improvement in survival of screen-detected cases is not necessarily equivalent to benefit?. Breast, 2003, 12, 299-301.	0.9	3
409	Letter to the Editor: Selective Screening for Scoliosis. Clinical Orthopaedics and Related Research, 2006, 445, 277-278.	0.7	3
410	Reply from Authors re: Michael Baum. Screening for Prostate Cancer: Can We Learn from the Mistakes of the Breast Screening Experience? Eur Urol 2013;64:540–1. European Urology, 2013, 64, 541-543.	0.9	3
411	Evaluation of Systematic Assessment of Asthma-Like Symptoms and Tobacco Smoke Exposure in Early Childhood by Well-Child Professionals: A Randomised Trial. PLoS ONE, 2014, 9, e90982.	1.1	3
412	Response. Journal of the National Cancer Institute, 2015, 107, djv111-djv111.	3.0	3
413	Lung cancer screening and its continuous risk assessment. Lancet Oncology, The, 2017, 18, 1434-1436.	5.1	3
414	Informed decision-making based on a leaflet in the context of prostate cancer screening. Patient Education and Counseling, 2019, 102, 1483-1489.	1.0	3

#	Article	IF	CITATIONS
415	A choice experiment to identify the most important elements of a successful cancer screening program according to those who research and manage such programs. International Journal of Health Planning and Management, 2019, 34, e34-e45.	0.7	3
416	Multi-Modality Imaging for Prevention of Coronary Artery Disease and Myocardial Infarction in the General Population: Ready for Prime Time?. Journal of Clinical Medicine, 2022, 11, 2965.	1.0	3
417	Fifteen Years of Population-Based Breast Cancer Screening in the Netherlands. Seminars in Breast Disease, 2007, 10, 72-82.	0.0	2
418	Foreword: Meeting the challenge of prostate cancer. European Journal of Cancer, 2010, 46, 3037-3039.	1.3	2
419	Mammography Screening and Breast Cancer Mortality—Response. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 870-871.	1.1	2
420	Increased nonâ€prostate cancer death risk in clinically diagnosed prostate cancer. BJU International, 2012, 110, 188-194.	1.3	2
421	Reply: Stage Distribution of Lung Cancers Detected by Computed Tomography Screening in the NELSON Trial. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1035-1036.	2.5	2
422	Raising the Bar for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 2014, 161, 532.	2.0	2
423	Reply to Koleva-Kolarova etÂal Breast, 2016, 27, 182-183.	0.9	2
424	Cost-Effectiveness Analysis of Lung Cancer Screening in the United States. Annals of Internal Medicine, 2020, 172, 706-707.	2.0	2
425	Breast cancer screening in Navarra: interpretation of a high detection rate at the first screening round and a low rate at the second round. International Journal of Cancer, 1997, 73, 464-469.	2.3	2
426	Risk results from screening for a high cardiovascular disease risk by means of traditional risk factor measurement or coronary artery calcium scoring in the ROBINSCA trial. European Heart Journal, 2020, 41, .	1.0	2
427	Testing at homethe screening of the future?. European Journal of Public Health, 2008, 19, 5-6.	0.1	1
428	Tipping the Balance of Benefits and Harms to Favor Screening Mammography Starting at Age 40 Years. Obstetrical and Gynecological Survey, 2012, 67, 481-482.	0.2	1
429	The effect of omitting an early population-based vision screen in the Netherlands: A micro-simulation model approach. Journal of Medical Screening, 2017, 24, 120-126.	1.1	1
430	Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. , 2001, 46, 87.		1
431	Abstract P6-13-01: MRI breast cancer screening compared to mammography in women with a familial risk: A multicenter randomized controlled trial. Cancer Research, 2019, 79, P6-13-01-P6-13-01.	0.4	1
432	One-off low-dose CT lung cancer screening in China: an appropriate strategy?. Lancet Respiratory Medicine,the, 2022, 10, 320-322.	5.2	1

#	Article	IF	CITATIONS
433	VA.4 Is there an upper age limit in screening?. Critical Reviews in Oncology/Hematology, 2007, 64, S18-S19.	2.0	Ο
434	Answer to the Letter to the Editor of I. Aprile et al. concerning "Health-related quality of life in patients with adolescent idiopathic scoliosis after treatment: short-term effects after brace or surgical treatment―(by Bunge EM et al. Eur Spine J 16: 83–89, 2007). European Spine Journal, 2007, 16, 1964-1964.	1.0	0
435	Are Low- and Middle-Income Countries Becoming the Victim of Western Debates About Breast Screening?. Breast Journal, 2010, 16, no-no.	0.4	Ο
436	Racial Disparities in Breast Cancer Mortality—Response. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1047-1047.	1.1	0
437	1450 THE TRUE BENEFIT OF PSA-SCREENING: MODELING THE IMPACT OF TRIAL SETTING AND PROTOCOL ON MORTALITY. Journal of Urology, 2012, 187, .	0.2	0
438	PD09-04 ESTIMATING THE HARMS AND BENEFITS OF PROSTATE CANCER SCREENING: COMPARING COMMON CLINICAL PRACTICE TO RECOMMENDED GOOD PRACTICE. Journal of Urology, 2016, 195, .	0.2	0
439	Sa1219 Impact of Mortality From Surgical Adenoma Removal on the Effectiveness of Colorectal Cancer Screening. Gastroenterology, 2016, 150, S253-S254.	0.6	0
440	Mo1706 Optimizing Screening Programs by Real-Time Monitoring: Outcomes of the National Colorectal Cancer FIT-Based Screening Program of the Netherlands. Gastroenterology, 2016, 150, S757-S758.	0.6	0
441	Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses. JAMA Oncology, 2016, 2, 277.	3.4	Ο
442	Optimum Management of Pulmonary Nodules. Radiology, 2017, 283, 917-919.	3.6	0
443	Authors' reply to: "Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlandsâ€. International Journal of Cancer, 2017, 141, 1709-1710.	2.3	0
444	Distinguishing between CISNET model results versus CISNET models. Cancer, 2018, 124, 1083-1084.	2.0	0
445	Re: Think before you leap. International Journal of Cancer, 2018, 142, 1507-1509.	2.3	Ο
446	The Future Is Prosperous. Journal of the National Cancer Institute, 2020, 112, 219-220.	3.0	0
447	Interpretation and adherence to the updated risk-stratified guideline for colonoscopy surveillance after polypectomy – a nationwide survey. Endoscopy International Open, 2020, 08, E1405-E1413.	0.9	0
448	Screening for Prostate Cancer. , 2003, , 683-707.		0
449	Abstract 1899: Validation of the Spitz lung cancer risk prediction model with the Dutch-Belgian randomized lung cancer screening trial (NELSON) cohort. , 2011, , .		0
450	Abstract P3-02-09: Cost-effectiveness of screening with additional MRI for women with familial risk for breast cancer without a genetic predisposition. , 2012, , .		0

#	Article	IF	CITATIONS
451	Incidence of interval cancer and detection rate of first screenings are inconsistent. BMJ: British Medical Journal, 1995, 310, 1002-1002.	2.4	Ο
452	Reproducibility of airway wall thickness measurements on CT in a lung cancer screening setting. , 2015, , .		0
453	Implementation of BEST (Barrier to Effective Screening Tool) to cancer in Europe. European Journal of Public Health, 2018, 28, .	0.1	Ο
454	Improved Harm/Benefit Ratio and Cost-effectiveness of Prostate Cancer Screening Using New Technologies. European Urology, 2022, , .	0.9	0
455	Reply to: Comments on "Finding the optimal mammography screening strategy: A costâ€effectiveness analysis of 920 modeled strategies― International Journal of Cancer, 2022, 151, 651-652.	2.3	Ο